Common profiles of Notch signaling differentiate disease-free survival in luminal type A and triple negative breast cancer
Metrics: PDF 1464 views | HTML 3694 views | ?
Magdalena Orzechowska1,*, Dorota Jędroszka1,*, Andrzej K. Bednarek1
1Department of Molecular Carcinogenesis, Medical University of Lodz, Lodz, 90-752, Poland
Andrzej K. Bednarek, email: firstname.lastname@example.org
Keywords: Notch, breast neoplasms, epithelial-to-mesenchymal transition, disease-free survival
Received: June 16, 2016 Accepted: October 29, 2016 Published: November 19, 2016
Breast cancer (BC) is characterized by high heterogeneity regarding its biology and clinical characteristics. The Notch pathway regulates such processes as organ modeling and epithelial-to-mesenchymal transition (EMT).
The aim of the study was to determine the effect of differential expression of Notch members on disease-free survival (DFS) in luminal type A (lumA) and triple negative (TN) BC.
The differential expression of 19 Notch members was examined in a TCGA BC cohort. DFS analysis was performed using the log-rank test (p<0.05). Biological differences between DFS groups were determined with Gene Set Enrichment Analysis (GSEA) (tTest, FDR<0.25). Common expression profiles according to Notch signaling were examined using ExpressCluster (K-means, mean centered, Euclidean distance metric).
The overexpression of HES1, LFNG and PSEN1 was found to be favorable for DFS in lumA, and lowered expression favorable for DFS in TN.
GSEA analysis showed that differential Notch signaling is associated with cell cycle, tissue architecture and remodeling. Particularly, targets of E2F, early stage S phase transcription factor, were upregulated in the lumA unfavorable group and the TN favorable group differentiated on a basis of HES1 and PSEN1 expression.
Summarizing, our analysis show significance of Notch signaling in BRCA progression through triggering EMT. Moreover, identification of numerous genes which overexpression is associated with disease recurrence may serve as a source of potential targets for a new anticancer therapy.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.